<DOC>
	<DOCNO>NCT02991274</DOCNO>
	<brief_summary>The study primary objective ass concordance T790M resistance mutation test hospital-based laboratory T790M resistance mutation test central laboratory .</brief_summary>
	<brief_title>ARTEMIS DIANE T790M ( An Amino Acid Substitution Position 790 EGFR , From Threonine ( T ) Methionine ( M ) ) Mutation Hospital Laboratories Comparison With Central Laboratory</brief_title>
	<detailed_description>This prospective , multi-center , real world study . 800 patient 80 different hospital site local T790M test different molecular testing platform central test Cobas platform . These two set data ( local T790M test central T790M test ) analyse compare assess concordance T790M testing platform .</detailed_description>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Histological cytological confirm locally advanced NSCLC ( stage IIIB ) metastatic ( stage IV ) NSCLC , amenable curative surgery radiotherapy . 3 . Documented EGFR mutation positive ( time since initial diagnosis NSCLC ) know associate EGFR TKI ( Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ) sensitivity . 4 . Patients progress follow prior therapy EGFRTKI agent . 5 . Patients consent provide tumour tissue blood . 1 . Previous ( within 6 month ) current treatment AZD9291 . 2 . Patients disagree participate study . 3 . Patients whose medical objection record use exist data medical practice scientific research .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>T790M</keyword>
	<keyword>EGFR ( Epidermal Growth Factor Receptor ) mutation</keyword>
	<keyword>NSCLC</keyword>
</DOC>